Medtronic has received US Food and Drug Administration (FDA) clearance for its Assurant cobalt iliac balloon-expandable stent system, designed to treat narrowed iliac arteries.
The approval is supported by the nine-month results from a trial that demonstrated technical, procedural and clinical success with the use of the Assurant stent.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Co-principal investigator William Gray said that the Assurant stent demonstrated good safety and long-term patency in the trial, with some of the lowest rates of nine-month target lesion revascularisation and target vessel revascularisation.
The new Medtronic stent uses a modular design to allow for smooth delivery to iliac artery lesions and conformability to the vessel wall.
